UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (20), p.5878-5890

2014

Volltextzugriff (PDF)

BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity

Cancer research (Chicago, Ill.), 2016-11, Vol.76 (21), p.6183-6192

2016

Volltextzugriff (PDF)

Abstract 976: ImmunoMap: a novel bioinformatics tool for immune cell repertoire analysis

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.976-976

2017

Volltextzugriff (PDF)

Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.62-62

2021

Volltextzugriff (PDF)

Abstract 4045: Dependence of human immune cell type, and impact of IL-7R or TLR1/2 agonism, upon trastuzumab-mediated ADCC

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.4045-4045

2024

Volltextzugriff (PDF)

Abstract 5687: Selective, chemically-induced degradation of BRM ( SMARCA2 ) enables in vivo efficacy in BRG1 ( SMARCA4 )-deficient xenograft tumor models

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5687-5687

2020

Volltextzugriff (PDF)

Abstract 7540: Impact of IL-2 and IL-7 on human regulatory T cell suppression and pembrolizumab-mediated reversal of human T cell exhaustion

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.7540-7540

2024

Volltextzugriff (PDF)

Abstract 3346: Testing the cancer stem cell hypothesis using the hybrid spheroid assay and Koch's postulates

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3346-3346

2016

Volltextzugriff (PDF)

Abstract 3578: A systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.3578-3578

2024

Volltextzugriff (PDF)

Abstract 3251: Assessing risk markers for oral cancer recurrence

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3251-3251

2014

Volltextzugriff (PDF)

Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT125-CT125

2022

Volltextzugriff (PDF)

Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT052-CT052

2023

Volltextzugriff (PDF)

Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.PD18-09-PD18-09

2023

Volltextzugriff (PDF)

Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.693-693

2014

Volltextzugriff (PDF)

Abstract 7474: T-cell responses across heart, blood, and tumor in patients with immune checkpoint inhibitor-related myocarditis (irMyocarditis)

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.7474-7474

2024

Volltextzugriff (PDF)

Abstract CT167: Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT167-CT167

2023

Volltextzugriff (PDF)

Abstract 136: Refining the molecular profile of colorectal tumors to expand prevention and treatment opportunities

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.136-136

2016

Volltextzugriff (PDF)

Abstract CT138: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT138-CT138

2022

Volltextzugriff (PDF)

Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1286-1286

2017

Volltextzugriff (PDF)

Abstract 770: Overcoming Trastuzumab resistance with the novel pan-erbb inhibitor AZD8931

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.770-770

2012

Volltextzugriff (PDF)

Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors : Consensus recommendations

Cancer research (Chicago, Ill.), 1996-07, Vol.56 (13), p.3010-3020

1996

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs

Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults

BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity

Abstract 976: ImmunoMap: a novel bioinformatics tool for immune cell repertoire analysis

Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC)

Abstract 4045: Dependence of human immune cell type, and impact of IL-7R or TLR1/2 agonism, upon trastuzumab-mediated ADCC

Abstract 5687: Selective, chemically-induced degradation of BRM ( SMARCA2 ) enables in vivo efficacy in BRG1 ( SMARCA4 )-deficient xenograft tumor models

Abstract 7540: Impact of IL-2 and IL-7 on human regulatory T cell suppression and pembrolizumab-mediated reversal of human T cell exhaustion

Abstract 3346: Testing the cancer stem cell hypothesis using the hybrid spheroid assay and Koch's postulates

Abstract 3578: A systematic NEN spheroid drug screen reveals a novel drug resistance mechanism in small bowel NETs

Abstract 3251: Assessing risk markers for oral cancer recurrence

Abstract CT125: A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas

Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas

Abstract PD18-09: ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Abstract 693: AXL tyrosine kinase inhibition selectively sensitizes mesenchymal cancer cells to antimitotic agents

Abstract 7474: T-cell responses across heart, blood, and tumor in patients with immune checkpoint inhibitor-related myocarditis (irMyocarditis)

Abstract CT167: Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study

Abstract 136: Refining the molecular profile of colorectal tumors to expand prevention and treatment opportunities

Abstract CT138: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study

Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors

Abstract 3007: Tobacco smoking, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project

Body mass index, waist circumference, type 2 diabetes mellitus and risk of liver cancer for U.S. adults

Abstract 770: Overcoming Trastuzumab resistance with the novel pan-erbb inhibitor AZD8931

Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors : Consensus recommendations

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Aktive Filter

Suchergebnisse filtern